Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.39 |
| ▸ | RORC | P51449 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 3/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24893394 | 0.91 | HTR2C (0.34) | HTR6RIPK1HTR2CSLC6A4HTR2A | |
| SCHEMBL1156788 | 0.91 | KDM4E (0.38) | HTR6KMT2AHTR2CSLC6A4NOD2 | |
| SCHEMBL1156621 | 0.89 | HTR2C (0.42) | HTR6KMT2AHTR2CSLC6A4 | |
| SCHEMBL2416549 | 0.89 | RIPK1 (0.39) | HTR6KMT2ARIPK1HTR2CSLC6A4 | |
| SCHEMBL1157010 | 0.89 | HTR6 (0.41) | HTR6CYP3A4CYP2D6 | |
| SCHEMBL4411752 | 0.88 | HTR2C (0.41) | HTR6KMT2AHTR2CSLC6A4 | |
| SCHEMBL31755113 | 0.87 | TSHR (0.38) | HTR6HTR2CSLC6A4PTGDR2 | |
| SCHEMBL1156168 | 0.85 | KMT2A (0.46) | HTR6KMT2AHCRTR1HCRTR2PTGDR2 | |
| SCHEMBL31755092 | 0.84 | HTR2C (0.37) | HTR6RIPK1HTR2CSLC6A4HTR2A | |
| SCHEMBL1278232 | 0.84 | HTR2C (0.35) | RORCHTR2CSLC6A4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048909-B2 | Proton pump inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-01 | — | — | US | disclosed |
| EP-2336107-A2 | Proton pump inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
| US-20110028476-A1 | PROTON PUMP INHIBITORS | KAJINO MASAHIRO | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028476-A1 | PROTON PUMP INHIBITORS | HRH2, HRH4, CYP2C19 | HTR6 1412/4885RORC 1849/4885CYP3A4 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.